lapatinib has been researched along with bq 123 in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (bq 123) | Trials (bq 123) | Recent Studies (post-2010) (bq 123) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 1,391 | 63 | 152 |
| Protein | Taxonomy | lapatinib (IC50) | bq 123 (IC50) |
|---|---|---|---|
| Endothelin-1 receptor | Homo sapiens (human) | 0.017 | |
| Endothelin-1 receptor | Rattus norvegicus (Norway rat) | 0.014 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jensen, RT; Mantey, SA; Moody, TW; Moreno, P; Ramos-Alvarez, I; Ridnour, L; Wink, D | 1 |
1 other study(ies) available for lapatinib and bq 123
| Article | Year |
|---|---|
Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Endothelins; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Peptides, Cyclic; Protein Kinase Inhibitors; Pyrrolidines; Quinazolines; Receptor, Endothelin A; Receptor, Endothelin B; Receptor, ErbB-2; Transcriptional Activation | 2017 |